 |
|||
|
In
the Spotlight .......................................................................................................................................................... 2012 ASCO GI Cancers Symposium Highlights
Positive Phase III Results of Regorafenib in mCRC Patients Who have Progressed after Standard Therapies Regorafenib (BAY 73-4506) is an oral multikinase inhibitor of a broad range of angiogenic, oncogenic, and stromal kinases. The Phase III CORRECT trial was conducted to evaluate efficacy and safety of regorafenib in patients with mCRC who had progressed after treatment with all approved standard therapies. Patients were randomized 2:1 to receive regorafenib (160 mg OD PO, 3 weeks on/1 week off) plus BSC (best supportive care), or placebo (PL) plus BSC. From May 2010 to March 2011, 760 patients were randomized (regorafenib: 505; PL: 255). ..........................................................................................................................................................Tumor of the Month - Ovarian Cancer .......................................................................................................................................................... Despite comprising a mere 3% of cancer cases in women, ovarian cancer is the fifth leading cause of cancer deaths in women in the US. According to the National Cancer Institute, there will be 22,280 new cases and 15,500 deaths from ovarian cancer in 2012 in the US. The relative 5-year survival rate is 46% but decreases to 28% if diagnosed after the disease has spread to distant organs and lymph nodes. Little progress has been made in diagnosing or treating this disease: in 1975, the relative survival was 34.8%. The lack of progress is due in part to the constellation of symptoms that are also found in a variety of other common conditions; the lack of simple, accurate diagnostics; the persistence of dormant cancer cells; and the lack of anatomical barriers to prevent ovarian cancer cells from disseminating to the peritoneal cavity. More than 90% of ovarian cancers are epithelial cancers (EOC), which arise from cells that cover the surface of the ovaries or those that line the inclusion cysts. The tumors have a great deal of heterogeneity. Germ cell ovarian cancers compose roughly 5% of cases and stromal ovarian tumors make up another 5% of cases. Primary peritoneal cancer looks like and is treated like ovarian cancer but derives from the peritoneum. .......................................................................................................................................................... |
Best Viewed on IE 7 |
||
 |
 |
||
 |
|||
      |
|||
|
|
|||
|
The E-newsletter team: Dr. Shirish Kumar, Sarika Manchanda, Dr. Vinamrata Bhatia, Kimberly Tully, Courtenay Veenis, Monica Tuli.
Copyright©2012 SMARTANALYST Inc. All rights reserved CLICK HERE unsubscribe from the list CLICK HERE for previous issues
|
At SMARTANALYST, we support the decision-making process for licensing, business development, new product planning, and R&D groups within pharmaceutical and biotech companies. We currently work with leading pharmaceutical and biotech firms globally. | ||
|
|
|||
